Shinebact Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-12-2024
- Paid Up Capital ₹ 1.00 M
as on 23-12-2024
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -18.37%
(FY 2022)
- Profit -2.11%
(FY 2022)
- Ebitda -23.06%
(FY 2022)
- Net Worth 18.74%
(FY 2022)
- Total Assets 49.37%
(FY 2022)
About Shinebact Biosciences
The Corporate was formerly known as Exon Biosciences Private Limited. The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Varadharajan Balasubramanian, Ganesan Sasikumar, Vijayakumar Kumar, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999TN2018PTC121858
- Company No.
121858
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Apr 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Shinebact Biosciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijayakumar Kumar  | Director | 03-Apr-2018 | Current |
| Varadharajan Balasubramanian | Director | 03-Apr-2018 | Current |
| Ganesan Sasikumar | Director | 03-Apr-2018 | Current |
| Pattabiraman Rubeshkumar | Director | 03-Apr-2018 | Current |
Financial Performance of Shinebact Biosciences.
Shinebact Biosciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 18.37% decrease. The company also saw a slight decrease in profitability, with a 2.11% decrease in profit. The company's net worth Soared by an impressive increase of 18.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shinebact Biosciences?
In 2020, Shinebact Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Amazing Biotech Private LimitedActive 12 years 1 monthVaradharajan Balasubramanian and Ganesan Sasikumar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shinebact Biosciences?
Unlock and access historical data on people associated with Shinebact Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shinebact Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shinebact Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
